Core Viewpoint - Sillodic Pharmaceuticals (01244) shares rose over 10%, currently up 13.96% at HKD 9.06, with a trading volume of HKD 17.58 million [1] Company Summary - Sillodic Pharmaceuticals recently announced that its self-developed nuclear medicine platform's first radiolabeled drug, 177Lu-PSMA-3D1015 injection, has completed the first patient dosing in the IIT study [1] - The study aims to evaluate the safety and preliminary efficacy of 3D1015 in patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) [1] - The company believes that 177Lu-PSMA-3D1015 injection has the potential to become a "best-in-class" nuclear medicine product, providing a safer and more effective treatment option for prostate cancer patients globally [1] Industry Summary - According to MEDraysintell, the global nuclear medicine market is expected to reach nearly USD 39 billion by 2032 [1] - The advancement of 177Lu-PSMA-3D1015 is seen as a step towards elevating China's nuclear medicine research to an internationally leading level [1]
思路迪医药股份涨超10% 自主研发新一代精准核药完成首例患者给药 核药市场潜力巨大